The bacteriophage T4 DNA packaging machine consists of a molecular motor assembled at the portal vertex of an icosahedral head. The ATP-powered motor packages the 56-μm-long, 170-kb viral genome into 120 nm × 86 nm head to near crystalline density. We engineered this machine to deliver genes and proteins into mammalian cells. DNA molecules were translocated into emptied phage head and its outer surface was decorated with proteins fused to outer capsid proteins, highly antigenic outer capsid protein (Hoc) and small outer capsid protein (Soc). T4 nanoparticles carrying reporter genes, vaccine candidates, functional enzymes, and targeting ligands were efficiently delivered into cells or targeted to antigenpresenting dendritic cells, and the delivered genes were abundantly expressed in vitro and in vivo. Mice delivered with a single dose of F1-V plague vaccine containing both gene and protein in the T4 head elicited robust antibody and cellular immune responses. This "progene delivery" approach might lead to new types of vaccines and genetic therapies.
D
elivery of recombinant genes and proteins into cells forms the core of molecular biology and biotechnology. Although numerous methods have been developed to deliver genes; electroporation (1), viral vectors (2) , and microinjection (3), protein delivery is less common (4, 5) . Moreover, no platforms currently exist that can efficiently deliver both genes and proteins (Table  S1 ). With the explosion of genomics and protein network databases, delivery of genes and proteins into target cells would be essential to generate basic understanding of mechanisms as well as to explore novel biomedical therapies. For instance, future treatments of complex genetic and infectious diseases such as cancer and AIDS might include delivery of genes and proteins in appropriate combinations, which we refer to as "progene delivery. " We have engineered the phage T4 DNA packaging machine into a high-capacity progene delivery vehicle. Tailed phages use powerful molecular machines to condense the highly negatively charged DNA genome inside a capsid to near crystalline density (>500 mg/mL). These machines generate forces as high as 80 pN to oppose the electrostatic repulsion and bending energies that resist DNA compaction (6) . The phage T4 packaging machine, one of the fastest (packaging rate up to ∼2000 bp/sec) and most powerful (power density, ∼5,000 kW/m 3 ) (7), consists of two essential components: an empty prohead and a molecular motor comprised of five subunits of the large terminase protein, gp17 (8, 9) (Fig. 1 A and B) .
Phage T4 head is decorated with two outer capsid proteins: Hoc (highly antigenic outer capsid protein; 155 copies/head) and Soc (small outer capsid protein; 870 copies/head) (10) (Fig. 1 C  and D) . The nanomolar affinity binding sites for Hoc and Soc appear after the prohead has undergone "expansion," a major conformational change in the capsid protein, gene product (gp)23* (* represents the cleaved form). The tadpole-shaped Soc (9 kDa) assembles as a trimer at the quasi threefold axes, clamping the adjacent capsomers and forming a reinforcing cage around the shell (11) (Fig. 1 C-E) . The linear fibers of Hoc (about 170 Å long; 41 kDa) each having a string of four domains, three of which are IgG-like domains, assemble at the center of hexameric capsomers (12) (Fig. 1 C, D, and F) . Hoc facilitates attachment of phage to bacteria. Soc and Hoc are not essential for phage infection but provide survival advantages for the virus (13) . The N and C termini of Soc (Fig. 1E ) and the N terminus of Hoc (Fig. 1F ) are well exposed, allowing efficient display of foreign proteins on the capsid surface (14) .
Recently, we constructed a neckless (13 amber), tailless (10 amber), hoc and soc deletion mutant that accumulates packaged heads (15) . In the classic assembly pathway, the packaging motor assembles on a prohead and after head maturation and (headful) genome packaging, the motor dissociates. Then, the neck proteins, gp13, gp14, and gp15, attach to the portal sealing off the packaged head. Tail and tail fibers attach to the neck, producing an infectious virion. In the neckless mutant, the packaged heads become unstable and release the DNA due to internal pressure, which is estimated to be ∼6 MPa, or >10 times the pressure in a champagne bottle (6, 16) . Unexpectedly, we discovered that the packaging motor can reassemble on this fully matured, emptied phage head and refill with any DNA (15) . The T4 packaging machine, thus, is promiscuous, neither discriminating the head on which it assembles nor the DNA that it packages.
These findings led us to ask whether the phage packaging machine could be reconfigured to deliver genes and proteins into mammalian cells. Conceivably, each head packaging several genes (17) , up to ∼170 kb, and displaying several proteins outside, up to ∼1,025 molecules (14, 18) , could deliver the entire "payload" into cells. Such a system would be attractive not only because of its large genetic capacity but also because T4 does not infect mammalian cells, is nontoxic, and has no preexisting immunity in the host. Here, we show that combinations of reporter genes, vaccine genes, functional enzymes, and targeting ligands can be incorporated into the T4 head and delivered into mammalian cells to near 100% efficiency. Our experiments further demonstrate that delivery can be targeted to antigen-presenting dendritic cells (DCs) and the delivered genes are abundantly expressed both in vitro and in vivo. Mice immunized with a single dose of "prime-boost" plague vaccine containing the recombinant F1-V gene from Yersinia pestis packaged inside the T4 head and the F1-V protein displayed outside elicited robust antibody and cellular immune responses. These studies established a unique phage-based mammalian gene and protein delivery system that could lead to novel vaccine and genetic therapies.
Results and Discussion
Experimental Design for Progene Delivery. A detailed experimental scheme was developed to quantitatively analyze progene delivery by T4. The T4 DNA packaging machine was first assembled by binding the gp17 subunits at the dodecameric portal (gp20) of empty phage head ( Fig. 2A) . Fueled by ATP, the machine packages DNA into the head (Fig. 2B ), up to ∼170 kb. Soc-and/ Author contributions: P.T., M.M., A.K.C., and V.B.R. designed research; P.T., M.M., B.S.M., and Z.Z. performed research; P.T., M.M., B.S.M., Z.Z., A.K.C., and V.B.R. analyzed data; and P.T. and V.B.R. wrote the paper.
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or Hoc-fused proteins/peptides were then added to decorate the capsid surface ( Fig. 2 C and D) . The number of DNA molecules packaged and the number of protein molecules displayed were quantified by agarose and polyacrylamide gel electrophoresis, respectively. The T4 nanoparticles were then added to mammalian cells. The particles bind to cells either nonspecifically (Fig.  2E ) or by recognizing a specific receptor on the cell surface (Fig. 2 F and G) and are internalized, presumably by endocytosis (Fig.   2H ). The surface displayed proteins (e.g., β-galactosidase) (Fig. 2I ) and the encapsidated DNA (e.g., luciferase and GFP genes) (Fig.  2J ) would be released into the cytosol. The protein function is expressed in the cytosol (Fig. 2I) , whereas the DNA enters the nucleus (Fig. 2K ) and primes transcription of cloned genes under the control of the strong CMV promoter (Fig. 2L ), leading to overexpression of luciferase and GFP proteins (Fig. 2M ).
T4 Progene Particles Are Efficiently Assembled in Vitro. We first isolated the neckless heads from Escherichia coli cells infected with 10-amber13-amber hoc-delsoc-del mutant (Fig. 3A) . Most of these heads, ∼90%, released the viral genome spontaneously, which was digested with DNase I. The emptied heads retained an ∼8-kb DNA inside, leaving the rest of the ∼162-kb space available for foreign DNA. The heads were purified by CsCl gradient centrifugation and ion-exchange chromatography (Fig. S1 ) and mixed with gp17 to reconstitute the functional packaging machine. These machines refilled the heads at high efficiency, as shown by bulk and singlemolecule assays (Fig. S2) . CryoEM indicated that most of the machines actively encapsidated DNA. The packaging reactions were terminated by the addition of DNase I to degrade the unpackaged DNA. The encapsidated and DNase I resistant DNA was released by treatment with proteinase K and quantified by agarose gel electrophoresis (SI Materials and Methods). Single (Fig.  3B ) or multiple plasmids, long ∼80-kb ligated DNA (up to ∼170 kb) or short 2.3-kb PCR-amplified DNA (Fig. 3C) were efficiently packaged. Quantification of the packaged eGFP (Fig. 3C Upper) and luciferase ( Fig. 3C Lower) plasmid DNA bands showed that the number of plasmid DNA molecules packaged per head increased with increasing ratio of DNA molecules to head particles in the reaction mixture ( Fig. 3B ; black arrows correspond to the packaged DNA). At the highest ratio used, 30:1, approximately 10 molecules of plasmid DNA were packaged per head. When two (or more) plasmid DNAs were present, both were packaged at roughly equal frequencies (Fig. 3C, lane 1) . Foreign peptides [cell penetration peptides (CPPs)] and proteins [β-galactosidase, dendritic cell specific receptor (DEC)205 monoclonal antibody (mAb), CD40 ligand (CD40L), etc.] were then arrayed on the surface by adding the Soc-and Hoc-fused recombinants to the reaction mixture containing the packaged heads, and the unbound Soc and Hoc proteins were removed by centrifugation and washing with buffer (SI Materials and Methods) ( Fig. 3D and Fig. S3 ). Soc and Hoc binding to capsid followed simple first-order kinetics, and the head (the cut-out of the head shows both the exterior and the interior) (A). Using the energy from ATP hydrolysis the motor packages DNA molecules into the head (B). Soc-fused proteins (C) and Hocfused CPPs or targeting molecules (D) were displayed on the heads. The head particles bind to cells either nonspecifically (general delivery) (E) or through a host receptor (targeted delivery) (F and G) and are internalized (H). The surface displayed protein (e.g., β-galactosidase) (I) and encapsidated DNA (e.g., luciferase and GFP genes) (J) are released into the cytosol. The DNA enters the nucleus (K), priming transcription (L), and expression of luciferase and GFP proteins (M).
copy number of bound protein was controlled by varying the ratio of Soc-or Hoc-fusion protein molecules to binding sites ( 
Engineered T4 Particles Efficiently Delivered Genes into Mammalian
Cells. Initial experiments showed that T4 delivery of the luciferase gene into HEK293T cells was very poor. However, when the particles were decorated with CPP-Tat (CPP-T) or CPP-Antp (CPP-P) ( Fig. 3D) , delivery was efficient, as shown by the appearance of high luciferase activity in the cell lysates ( Fig. 3 E-H). CPPs are 20-to 30-aa peptides rich in basic amino acids that facilitate passage of attached cargo molecules across the cell membrane (19) . Tat and Antp refer to CPPs of HIV-1 transactivator protein and Drosophila antennapedia homeobox protein, respectively (19) (Fig. S3) . Luciferase activity reached the maximum at 10 5 heads per cell (Fig. 3E ). The activity appeared by as early as 5 h, reached a peak by about 16 h, and was sustained for at least 30 h (Fig. S4A) .
Luciferase activity increased with increasing copy number of CPP (Fig. 3F and Fig. S4B) ; however, at a given copy number, CPP-T is 3.3-fold more effective than CPP-P (Fig. 3G) . Hoc-CPP-T (Hoc-T) was superior to Soc-CPP-T (Soc-T); at a Hoc-T copy number of 155 per head, it showed 5.4-fold higher luciferase activity than Soc-T, even though Soc-T's copy number at 870 copies per head is 5.6 times greater than that of Hoc-T (Fig. 3G ). This increased delivery was presumably because the Hoc-fused CPP is positioned ∼170 Å away from capsid surface (height of Hoc fiber), thus having greater reach to contact the cell membrane of the mammalian cell compared with Soc-CPP that is nearly "glued" to the capsid wall (11, 12) (Fig. 1 A and F) . Combining Hoc-CPP and Soc-CPP further increased delivery efficiency by 1.9-fold (Fig. 3H) . The delivery efficiency was roughly the same whether the packaged DNA was a plasmid, short PCR-amplified DNA, or ligated into a long concatemer (Fig. 3J) . Parallel experiments using another plasmid, pEGFP-C1, gave similar results, with nearly 100% of cells showing green fluorescence (Fig. 3I) .
Proheads or isometric phage heads can also be used as delivery vehicles (Fig. S4 ), but the fully mature emptied phage heads, which are extremely stable and can be produced in large quantities (∼5 × 10 13 particles per liter of culture), were the heads of choice. Preliminary experiments using inhibitors indicated that the T4 head delivery was mediated by an endocytic pathway that is energy-dependent and requires actin polymerization but not clathrin or caveolin (Fig. S5 A and B) . No significant toxicity was observed following T4 delivery, even at a ratio of 10 6 head particles per cell ( Fig. S5 C and D) .
The T4 delivery efficiency was assessed to be very high, approaching as many as 10 5 luminescence units per cell (Fig.  3K ). To determine how this efficiency compared with lipofectamine and adeno-associated virus (AAV), the two most efficient transfection systems currently available, luciferase gene was delivered into HEK293T cells under conditions that are optimal for each of these systems. The data showed that the T4 efficiency was similar to that of the lipofectamine but ∼3.3 times higher than that of the AAV-DJ vector, the most efficient AAV vector reported to date (20) (Fig. 3K ).
Targeted Delivery of Genes and Proteins into DCs by T4. The antigenpresenting DCs were chosen to test whether T4 delivery can be targeted to specific cells. DCs are critical for vaccine uptake and induction of humoral as well as cellular immune responses (21) . We hypothesized that displaying a DC-specific ligand on the capsid lattice would enable T4 to capture DCs leading to endocytosis and delivery of the attached cargo. To test this hypothesis, the DEC205mAb or the CD40 ligand (CD40L), which respectively recognize the DC-specific DEC205 receptor (22) and CD40 (23), were displayed on the T4 heads. The heads were first packaged with luciferase and/or eGFP genes and incubated with the Hoc-GG fusion protein plus DEC205 mAb (Fig. S6) . The GG fusion contained two tandemly linked 122-aa IgG binding domains of protein G (24) from Streptomyces. When attached to T4 head through Hoc, these domains captured the Fc region of IgG and formed arrays of DEC205 mAb on the head with their receptor binding Fab regions well exposed (Fig. 4 A and G and Fig. S6 C and D) . These particles efficiently delivered the packaged luciferase gene into mouse DC2.4 cells (25) but were unable to do so into nonspecific cells, such as Hep3B cells, that lacked the receptor (Fig. 4B) . Delivery efficiency was nearly 100% in several independent experiments (Fig. 4C) . When both the luciferase and eGFP genes were packaged into the same (In this experiment, due to the low capacity of AAV, the shorter pLuci plasmid was used instead of the psiCHECK2). Error bars represent SD; **P < 0.01; ***P < 0.001.
head, the heads delivered both the genes to near 100% efficiency as shown by the presence of both the luciferase and green fluorescence signals in the HEK293T cells (Fig. S7A ), but not in the control cells (Fig. S7B) . Similar results were also obtained using the displayed CD40L fused to the N terminus of Hoc. We then tested protein delivery into DCs using the 129-kDa E. coli β-galactosidase as the model protein. This is a stringent test because β-galactosidase is functional only as a tetramer. Therefore, the Soc-fused protein must oligomerize into a >500-kDa complex and be efficiently displayed and delivered. A β-galactosidase-Soc recombinant was constructed and purified (Fig.  S8) . The fusion protein was efficiently displayed on T4 heads (Fig. 4D) , and the resultant heads showed β-galactosidase activity (Fig. 4E) . Hoc-fused CPP-T or DEC205 mAb was then decorated on the same heads (Fig. 4 F and G, I and V). These heads, when incubated with DCs, showed delivery of β-galactosidase into nearly 100% of the cells, as shown by the appearance of blue X-Gal signal (Fig. 4 F, IV and VIII) . Control particles containing either no targeting ligand (Fig. 4 F, III and VII) or the soluble enzyme alone (Fig. 4 F, II and VI) showed poor to no signal. Can T4 simultaneously deliver both genes and proteins into cells? To address this question, the heads were first packaged with luciferase and eGFP plasmids. The surface was then decorated with β-galactosidase as Soc fusion, and with CPP (Fig. 4H ) or DEC205 mAb (Fig. 4I ) as Hoc fusion. We then tested whether the entire payload could be delivered into DCs. As shown in Fig.  4 H and I, nearly 100% of cells showed strong signals for all three markers, demonstrating that the T4 nanoparticles efficiently delivered two different genes as well as large oligomeric complexes into DCs. The same was observed using a series of other proteins displayed on the head, including the F1-V fusion protein from Y. pestis (see below).
In Vivo T4 Delivery. In vivo T4 delivery was tested using a mouse model. Four groups of mice were injected intramuscularly with T4 heads packaged with the luciferase plasmid. The first group received heads containing no displayed ligand, whereas the second, third, and fourth groups received heads displayed with DEC205mAb, CD40L, and CPP-T, respectively. At different time points after injection, mice were injected with the bioluminescence substrate D-Luciferin, and the entire body was imaged. Unexpectedly, the strongest luciferase signal was observed in the first group, which received heads containing no displayed ligand (Fig. 5A) ; these same particles showed very poor delivery in vitro (Fig. 3 E and I, I-III) . Furthermore, the signal appeared as early as 6 h after injection, suggesting that the muscle cells had taken up the T4 nanoparticles and expressed the delivered DNA efficiently at the site of injection. A time-course analysis showed that the luciferase signal was seen for at least 14 d using the standard luciferase expression cassette, and for at least 30 d if the cassette is flanked by AAV inverted terminal repeats (ITRs prime DNA replication of the delivered gene) (Fig. 5 B and  C) . On the other hand, the DEC205mAb-and CD40L-displayed particles showed weak to no luciferase signal, and the signal disappeared rapidly: By 16 h, hardly any signal remained at the site of injection (Fig. 5 A, compare 3 and 4 and 5 and 6 with 1 and 2). These data suggested that the DCs that took up the DEC205mAb-or CD40L-displayed T4 particles migrated to other parts of the body, e.g., lymph nodes and spleen, thereby diluting the signal to below the sensitivity of bioluminescence imaging (similar observations were made in ref. 26 ). The CPPdisplayed group also behaved similarly (Fig. 5 A, 7 and 8 ), but whether this was due to migration of DCs and/or whether other types of cells were also involved requires further investigation. To further confirm that the lack of signal was due to migration of DCs rather than to lack of delivery, another control experiment was performed by delivering the same amount of luciferase DNA into mice using heads containing either no ligand or the displayed CD40L (Fig. 5 D, 1) . The CD40L group that showed no signal (Fig. 5 D, 3 ) induced similar titers of anti-luciferase antibodies (Fig. 5E) as the no-ligand group that showed strong signal (Fig. 5  D, 2) . In addition, the DC-targeted group elicited strong cellular immune responses (see below). Taken together, these data demonstrate that T4 delivery is efficient in vivo, and the delivery could be either localized to myocytes at the site of injection or dispersed into the body through migration of DCs. In the case of the former, the gene product is localized to the muscle (although it could be secreted into the body by attaching a signal peptide), whereas in the targeted group, the gene product and the peptides derived from it travel, but importantly, are presented to DCinteracting cells such as the T cells and B cells (21) (see below).
Single Dose of T4 Delivered Plague Vaccine Induced Robust Humoral and Cellular Immune Responses. An ideal vaccine would stimulate both the humoral (Th2) and cellular (Th1) arms of the immune system (27) . Delivering the vaccine in both forms, as antigen and as expressible DNA, might prime as well as boost the immune system ("prime-boost" vaccine), stimulating the Th1 and Th2 responses (28) . This prime-boost approach might be particularly important for combating complex infectious agents such as HIV-1, malaria, and tuberculosis (TB) for which no effective vaccines have yet been developed by traditional methods. Plague, also known as Black Death, caused by Y. pestis might also require the induction of antibody and cellular immune responses (29) . The two principal candidates for a plague vaccine are the capsular protein [capsule antigen family 1 (Caf1) or F1, 16 kDa] and the low calcium response V antigen (LcrV or V, 37 kDa), a key component of the type 3 secretion system. Current plague vaccines containing F1 and V recombinant proteins elicit strong antibody responses but poor cellular immune responses (29) . This is a common problem encountered by conventional subunit vaccines. We asked whether the T4 nanoparticles delivering both F1-V DNA and F1-V protein can modify the quality of immune responses. Furthermore, because the T4-delivered gene continues to be expressed for weeks, we asked whether a single dose of vaccine would be sufficient to induce strong immune responses.
These questions were addressed by (i) cloning a mutant F1-V gene that produces soluble monomeric F1-V fusion protein under the control of the strong CMV promoter and packaging the F1-V DNA into T4 head, and (ii) fusing the mutant F1-V protein to the N terminus of Soc and displaying the fusion protein on the capsid surface. Groups of mice were immunized intramuscularly with a single dose of F1-V vaccine in various combinations (Fig. 6A) . For prime-boost vaccination (group 5), mice were injected with T4 heads (∼5 × 10 11 particles) packaged with ∼25 μg of F1-V DNA and displayed with ∼30 μg of F1-V protein plus ∼100 copies per head of DEC205mAb. Control groups included naïve, F1-V protein adjuvanted with Alum, heads packaged with F1-V DNA, and heads displayed with F1-V protein. No adjuvant was included in any of the T4-vaccinated groups. ELISA of sera 4 wk after immunization showed that strong antibody responses were induced in all of the groups; end point titers as high as 7.5 × 10 4 were attained in some of the mice (Fig. 6B) . However, strong cellular responses were elicited only in two of the groups: the T4 DNA group and the T4 prime-boost group that delivered both the F1-V DNA and the F1-V protein to DCs (Fig. 6C) . Indeed, the latter group produced the strongest IFNγ response. Unexpectedly, splenocytes from this group showed high incidence of Elispots even without stimulation with F1-V antigen ( Fig. 6C ; compare the red unstimulated column in group 5 with the same from rest of the groups). The counts increased further by F1-V stimulation (Fig. 6C) . These results are consistent with our hypothesis that T4 vaccine delivery into DCs induces abundant expression of F1-V and presentation to the immune system for a long period, in turn leading to continuous stimulation of T cells.
The above results demonstrated the application of T4 progene delivery for prime-boost vaccination. A single dose of T4 vaccine without any adjuvant was sufficient to stimulate both arms of the immune system. In addition, unlike the conventional vaccines, the immune system in T4 vaccinated animals remain activated for weeks after immunization. Thus, T4 appears to be a good platform for future development of efficacious prime-boost vaccines.
Conclusions
The above series of experiments established the phage T4 DNA packaging machine as a unique type of gene and protein delivery platform. With well understood structural and mechanistic A mutant F1 gene from Y. pestis was fused to the N terminus of V gene and the F1-V fusion was then fused to the N terminus of Soc gene. The F1-V-Soc fusion protein was purified as a 66 kDa monomer. For the DNA group (#4), F1-V was cloned under the control of the CMV promoter. Spleens were harvested from three mice from each group at day 21 for Elispot assays, and sera were collected at day 28 for ELISAs. The ELISA (B) and Elispot (C) assays were performed according to the procedures described in Materials and Methods. SFC refers to spot-forming cells expressing IFN-γ. Error bars represent SD; **P < 0.01; ***P < 0.001. features ( Fig. 1 ; the 170-kb-capacity head, the promiscuous packaging motor, the 1,025 molecule capacity surface lattice, Soc protein with exposed termini, and ∼170-Å-long Hoc fiber to capture target cells), T4 offers many options to engineer the nanoparticle for diverse applications. Unlike the existing systems that are mostly single featured and have limited capacity (Table S1) , the T4 applications range from simple in vitro delivery of genes and proteins to complex in vivo deliveries involving combinations of genes, proteins, oligomeric complexes, and targeting molecules to treat diseases. A set of key experiments have been selected to demonstrate these broad applications. The data show that T4 efficiently delivered single or multiple genes, either as plasmids, PCR-amplified DNAs, or concatemerized DNA. At the same time, single or multiple proteins were delivered, either as short peptides, fulllength proteins, or large oligomeric complexes. Different parts of the nanoparticle were engineered to carry out different tasks but integrated to generate a desired outcome. For instance, one part (Hoc) was dedicated to target the nanoparticles to specific cells, whereas another part (Soc) was designed to transiently express a new function, and yet another part (capsid interior) to overexpress an antigen for an extended period. Thus, T4 offers an advanced system for delivery of recombinant DNA and protein molecules.
The phage T4 platform offers several technical advantages that make it easily adaptable to any laboratory. Bacterially derived, the T4 head is noninfectious, nontoxic, and has no preexisting immunity. The two main components of the T4 platform, heads and packaging motor (gp17), can be prepared relatively easily from E. coli in large quantities (∼5 × 10 13 heads, or 5 mg of gp17 per liter of culture). Both are very stable and retain activity after storage for at least 2 y at −70°C. The assembly steps are relatively simple, performed in a single tube, and completed in about 3 h, and each step can be quantified. As shown, a series of customized nanoparticles with different compositions of genes and proteins could be prepared in a single experiment.
T4 progene delivery offers avenues for developing useful biomedical therapies. We have demonstrated a prime-boost vaccination approach against pneumonic plague that elicits strong antibody and cellular immune responses. This approach could be used broadly to develop efficacious vaccines against complex infectious agents such as HIV-1, malaria, and TB. T4 heads delivering recombinase and targeting molecules displayed outside, and genomic DNA and siRNA genes packaged inside, could be used in cancer therapy, either to kill cancer cells by induction of apoptosis or to reverse the cancer phenotype by turning off certain oncogenes (30) . T4 delivery might allow safe and efficient reprograming of pluripotent stem cells by delivering transcription factor genes and proteins such as c-Myc, kruppel-like factor 4 (Klf4), sex determining region Y box 2 (Sox2), and octamer-binding transcription factor (Oct3/4), as well as replacing the defective gene with a functional gene by in vivo delivery of a long stretch of genomic DNA (31) .
Materials and Methods
Packaging assays were performed using Hoc − Soc − phage T4 heads, gp17, and plasmid DNA. Protein display was carried out by adding Hoc-and/or Socfused proteins to the packaged heads. The heads were then incubated with HEK293 or DC2.4 cells for gene and protein delivery. After washing with buffer, the cells were analyzed for luciferase and β-galactosidase activities. For in vivo delivery, the heads were injected into mice by intramuscular route and imaged. These and the immunological assays such as ELISA and Elispot are described in detail in SI Materials and Methods. The protocols for mouse studies were approved by the Institutional Animal Care and Use Committee of the University of Texas Medical Branch, Galveston, TX.
